×
About 8,903 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  3,344 results

The preoperative prognostic value of the radiomics nomogram based on CT combined with m...
https://doi.org/10.1186/s12957-021-02162-0 10.3322/caac.21262 10.1007/s12029-018-0084-5 10.1097/MD.0000000000018191 10.1186/s13046-019-1477-4 10.1001/jamasurg.2013.5137 10.1200/JCO.2012.41.5984 10.1001/archsurg.2012.1962 10.1097/SLA.0b013e318176c4d3 10.1097/SLA.0b013e3182a5c985 10.1200/JCO.2011.35.6519 10.1093/annonc/mdq650 10.1016/j.jhep.2014.01.021 10.1016/j.bbadis.2017.08.002 10.1245/s10434-020-08486-7 10.1007/s00270-020-02569-4 10.1016/j.crad.2004.07.008 10.1148/rg.2017170056 10.1102/1470-7330.2013.9045 10.1186/s40644-020-00323-0 10.3389/fonc.2018.00360 10.7150/thno.34149 10.1200/JCO.2007.12.9791 10.1016/S1470-2045(14)71116-7 10.1148/radiol.11101454 10.1007/s00261-015-0629-z 10.1158/0008-5472.CAN-18-0125 10.1002/sim.3148 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 10.1001/jama.2015.37 10.1093/eurheartj/ehu207 10.1007/s00330-019-06142-7 10.1016/j.hpb.2018.05.017 10.1001/jamasurg.2020.1973 10.3892/or.2013.2290 10.1002/hep.510280404 10.1016/j.suc.2018.12.004 10.1245/s10434-018-6669-1 10.1186/s40644-019-0234-4 10.2967/jnumed.116.173708 10.1002/mp.12123 10.2967/jnumed.116.181859 10.1038/nbt1306 10.1016/j.ccell.2017.05.009 10.3389/fonc.2016.00071 10.1007/s00330-019-06583-0 10.1007/s00259-019-04495-1
World Journal of Surgical Oncology; Tang Y, Zhang T et. al.

Aug 3rd, 2021 - Intrahepatic cholangiocarcinoma is an aggressive liver carcinoma with increasing incidence and mortality. A good auxiliary prognostic prediction tool is desperately needed for the development of treatment strategies. The purpose of this study was ...

Perihilar Cholangiocarcinoma-Novel Benchmark Values for Surgical and Oncological Outcom...
https://doi.org/10.1097/SLA.0000000000005103
Annals of Surgery; Mueller M, Breuer E et. al.

Aug 3rd, 2021 - The aim of this study was to define robust benchmark values for the surgical treatment of perihilar cholangiocarcinomas (PHC) to enable unbiased comparisons. Despite ongoing efforts, postoperative mortality and morbidity remains high after complex...

Right-sided resection with standard or selective portal vein resection in patients with...
https://doi.org/10.1016/j.hpb.2021.06.429
HPB : the Official Journal of the International Hepato Pa... Franken LC, Benzing C et. al.

Aug 1st, 2021 - Standard portal vein resection (PVR) has been proposed to improve oncological outcomes in patients with perihilar cholangiocarcinoma (PHC), however it potentially introduces an increased risk of morbidity. The policy in Amsterdam UMC(AMC) is to re...

Prognostic impact of tumor vascularity on CT in resectable intrahepatic cholangiocarcin...
https://doi.org/10.1016/j.hpb.2021.06.424
HPB : the Official Journal of the International Hepato Pa... Park HM, Jang HY et. al.

Jul 31st, 2021 - We investigated the vascularity of intrahepatic cholangiocarcinoma (ICC) on computed tomography (CT) images and its association with ICC recurrence after surgery and prognosis after recurrence. In this retrospective study, the data of patients who...

Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P4...
https://doi.org/10.1124/dmd.121.000508
Drug Metabolism and Disposition: the Biological Fate of C... Tang LWT, Teng JW et. al.

Jul 31st, 2021 - Infigratinib (INF) is a promising selective inhibitor of fibroblast growth factor receptors 1-3 that has recently been accorded both orphan drug designation and priority review status by the U.S Food and Drug Administration for the treatment of ad...

see more →

Guidelines  5 results

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 24th, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Hilar cholangiocarcinoma: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527854
HPB : the Official Journal of the International Hepato Pa... Mansour JC, Aloia TA et. al.

Jul 15th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Asia-Pacific consensus recommendations for endoscopic and interventional management of ...
https://doi.org/10.1111/jgh.12128
Journal of Gastroenterology and Hepatology; Rerknimitr R, Angsuwatcharakon P et. al.

Jan 29th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Midd...
https://doi.org/10.6004/jnccn.2010.0123
Journal of the National Comprehensive Cancer Network : JN... Yusuf MA, Kapoor VK et. al.

May 11th, 2011 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers address hepatocellular cancer, cancer of the gallbladder, extrahepatic cholangiocarcinoma, and intrahepatic cholangiocarcinoma. Hepatocellular cancer inci...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  114 results

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
https://clinicaltrials.gov/ct2/show/NCT03212274

May 5th, 2020 - PRIMARY OBJECTIVE: I. To estimate the overall response rates of olaparib in subjects with recurrent/progressive IDH1/2-mutant solid tumors, who will be recruited to 3 cohorts: a. glioma, b. cholangiocarcinoma, c. other solid malignant tumors. SECO...

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
https://clinicaltrials.gov/ct2/show/NCT03656536

Apr 27th, 2020 - The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03230318

Apr 7th, 2020 - This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcino...

Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT02456714

Mar 10th, 2020 - Cholangiocarcinoma, is a malignant gastrointestinal tumor of low incidence with a poor prognosis. Chemotherapy is the most common treatment for advanced disease. On the basis of a phase III clinical study, cisplatin plus gemcitabine is considered ...

Stereotactic Body Radiotherapy for Liver Tumors
https://clinicaltrials.gov/ct2/show/NCT01347333

Mar 3rd, 2020 - This study is a single site, non-randomized, prospective, phase IV trial. Composed of 4 patient groups: Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes Unresectab...

see more →

News  83 results

Novel Drug Approved by FDA for Some Bile Duct Cancers
https://www.medscape.com/viewarticle/952247

Jun 1st, 2021 - A novel drug, infigratinib (Truseltiq), is now available in the United States for adults with previously treated unresectable bile duct cancer harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. The agent is an o...

Europe Approves Pemigatinib for Bile Duct Cancer
https://www.medscape.com/viewarticle/948452

Mar 31st, 2021 - The European Commission has approved the oral targeted therapy pemigatinib (Pemazyre) for the treatment of locally advanced or metastatic cholangiocarcinoma, a rare cancer of the bile ducts. The indication is for patients with a fibroblast growth ...

Paving the Way for Diversity in Clinical Trials
https://www.medscape.com/viewarticle/947972

Mar 23rd, 2021 - "I'm the first person in my circle of family and friends to participate in a clinical trial." Five years ago, Rhonda Long was diagnosed with cholangiocarcinoma, a rare bile duct cancer that's seen in only about 8,000 Americans each year. At the ti...

Neoadjuvant Chemo for Intrahepatic Cholangiocarcinoma May Prolong Life
https://www.medscape.com/viewarticle/947254

Mar 12th, 2021 - NEW YORK (Reuters Health) - For patients with intrahepatic cholangiocarcinoma (ICC), the benefits of neoadjuvant chemotherapy (NAC) may extend beyond downstaging borderline resectable disease to improved overall survival, according to a small retr...

First Guideline on NGS Testing in Cancer, From ESMO
https://www.medscape.com/viewarticle/936478

Aug 28th, 2020 - Recommendations on the use of next-generation sequencing (NGS) tests for patients with metastatic cancer have been issued by the European Society for Medical Oncology (ESMO), the first recommendations of their kind to be published by any medical s...

see more →

Patient Education  13 results see all →